NCT02014402View on ClinicalTrials.gov

Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Hemostasis
Interventions
BIOLOGICAL

Human thrombin

Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges

BIOLOGICAL

Bovine thrombin

Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges

Trial Locations (20)

10029

600, New York

12601

606, Poughkeepsie

20007

601, Washington D.C.

21201

905, Baltimore

27599

508, Chapel Hill

32216

501, 901, Jacksonville

32611

507, Gainesville

39216

902, Jackson

40509

804, Lexington

60208

604, Evanston

76107

503, Fort Worth

77024

900, Houston

80303

803, Boulder

84132

605, Salt Lake City

85712

805, Tucson

89144

800, Las Vegas

90048

602, Los Angeles

91105

700, 801, Pasadena

99208

802, Spokane

06102

908, Hartford

All Listed Sponsors
lead

Instituto Grifols, S.A.

INDUSTRY

NCT02014402 - Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery | Biotech Hunter | Biotech Hunter